Physician profile
Steven W Robison
NPI 1710056577
$2,756.57
in general payments reported to CMS, 2019-2025
18 companies · $2,138 in 2025
The $2,138 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.44 · 2020: $18.62 · 2021: $109 · 2022: $85.61 · 2023: $236 · 2024: $85.30 · 2025: $2,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,618 · Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,618.12 |
| Food and Beverage | $841.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,065.25 | 2019-2025 | |
| Abbvie INC. | $239.22 | 2019-2025 | Liletta |
| Astellas Pharma US INC | $132.64 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $120.28 | 2023 | Acessa Provu System |
| Daiichi Sankyo INC. | $61.62 | 2021-2024 | Injectafer |
| Coloplast Corp | $30.16 | 2021 | |
| Amgen INC. | $25.96 | 2019-2022 | |
| Therapeuticsmd, INC. | $25.02 | 2019-2021 | |
| Exeltis, USA INC. | $16.63 | 2022 | |
| Novo Nordisk INC | $14.38 | 2025 | Wegovy |
| Lilly USA, LLC | $12.66 | 2021 | |
| Mayne Pharma Commercial LLC | $6.82 | 2023 | |
| Organon LLC | $5.93 | 2025 | Jada System |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Robison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.